Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.60 |
| ▸ | FLT1 | P17948 | 2/20 | 0.60 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.60 |
| ▸ | FLT4 | P35916 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | MERTK | Q12866 | 1/20 | 0.60 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.60 |
| ▸ | SYK | P43405 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14024560 | 1.00 | KDR (0.60) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL14024555 | 0.89 | KDR (0.57) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL14760641 | 0.89 | KDR (0.57) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL15494822 | 0.86 | KDR (0.63) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL14024407 | 0.85 | MAOB (0.48) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL14760542 | 0.85 | MAOB (0.48) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL14024557 | 0.82 | KDR (0.69) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL15494826 | 0.82 | KDR (0.62) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL15494873 | 0.81 | KDR (0.62) | KDRFLT1FGFR1FLT4FLT3 | |
| SCHEMBL14024746 | 0.81 | KDR (0.63) | KDRFLT1FGFR1FLT4FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2154967-B9 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-07-23 | — | — | EP | claimed |
| EP-2154967-B1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-03-05 | — | — | EP | claimed |
| US-8901143-B2 | Pyrimidine derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2014-12-02 | — | — | US | disclosed |
| EP-2154967-B9 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-07-23 | — | — | EP | disclosed |
| EP-2154967-B1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2014-03-05 | — | — | EP | disclosed |
| US-20130065890-A1 | PYRIMIDINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065890-A1 | PYRIMIDINE DERIVATIVES | TYMS, KDR, FLT4 | KDR 2/4885FLT1 7/4885FGFR1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.